RDEA 806

Drug Profile

RDEA 806

Alternative Names: 0481806 - Ardea Biosciences; AR 806; RDE-806; RDEA806; VRX-806

Latest Information Update: 30 May 2014

Price : $50

At a glance

  • Originator Valeant Pharmaceuticals International
  • Developer Ardea Biosciences
  • Class Antigouts; Antiretrovirals; Benzoic acids; Small molecules; Triazoles
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 30 May 2014 Discontinued - Phase-II for HIV infections in Europe, including Germany and the UK prior to May 2014 (PO)
  • 20 Jun 2012 Ardea Biosciences has been acquired by AstraZeneca
  • 03 Feb 2011 RDEA 806 is still available for licensing as of 03 Feb 2011. http://www.ardeabio.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top